Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Articles Tagged With:

  • Comfort Pack reduces anxiety, improves care

    An overnight delivery of pain medication that took four days and a charge of $125 for eight pills from a hospital pharmacy are two of the reasons that the staff at Hospice of the Hills in Rapid City, SD, started looking for a new way to help patients with emergency needs.
  • States expanding CD-PAS programs to offer flexibility

    Consumer direction of personal assistance services (CD-PAS) can offer Medicaid beneficiaries flexibility and independence to individualize their services. Analysts recognize that having greater control over these services is a high priority for some, but not all, disabled Medicaid beneficiaries.
  • HHA managers face difficult decisions in financial crises

    It's a tough time to be a home health manager. For years, you've implemented new processes and new services designed to strengthen your agency, but it's hard to fight an economic environment that is forcing all industries to reevaluate how they conduct business.
  • Product pipeline: Terumo in pivotal trial for DuraHeart

    Terumo Heart (Ann Arbor, Michigan) moved another step closer in its quest to release its DuraHeart Left Ventricular Assist System on the market, after the Institutional Review Board of the University of Michigan voted in late June to move forward with the device's pivotal trial for a bridge-to-transplant indication.
  • Personnel file

    AGA Medical Holdings; Boston Scientific; Cambridge Heart; FlowCardia; MedCath; Quintiles Transnational; Signalife; Stereotaxis; Xtent
  • Pharma developments: Solo or with tPA, is Gleevec a potential stroke treatmen

    Despite the fact that it is the only FDA-approved drug to treat ischemic stroke, Activase, also known as tissue plasminogen activator (tPA), a product from Genentech (South San Francisco, California) is not used in the majority of cases for which it is approved.
  • Remote, follow-on monitoring attracts growing spotlight

    SAN FRANCISCO Remote monitoring of implanted cardiac devices is hot at least at the level of discussion during scientific conferences, if not at the level of reimbursement of such services. But one step at a time: This technology clearly is adding more evidence concerning efficacy, if not clear cost-effectiveness.
  • CD&D at EuroPCR 2008: From valves to vascular protection: Going interventional

    BARCELONA, Spain EuroPCR, a prestigious meeting organized by the European Association of Percutaneous Cardiovascular Interventions (EAPCI), an association of the European Society of Cardiology (Sophia Antipolis, France) and a group focused on interventional devices used for diagnosis and treatment of cardiovascular disease, is the leading interventional meeting in Europe and an important forum for introducing new devices.
  • Market updates: JAMA study: DES benefits outweigh risks

    After more than two years of clinical data linking drug-eluting stents (DES) with an increased risk of stent thrombosis compared to their bare-metal cousins, a study in the Journal of the American Medical Association (JAMA) may shed some positive light on the DES space.
  • Agreements

    Cook Medical; HealthTrust Purchasing Group; Freescale Semiconductor; Monebo Technologies; HemCon Medical Technologies; SanguiBioTech; LifeScan; ResMed; Johnson & Johnson; IDev Technologies; YMed; Positron; Disease Management; NuView Radiopharmaceuticals